Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $199.44.
A number of analysts recently issued reports on RGEN shares. Benchmark lowered their target price on Repligen from $230.00 to $210.00 in a research note on Wednesday, May 3rd. Stifel Nicolaus lowered their target price on Repligen from $210.00 to $200.00 in a research note on Wednesday, June 28th. Stephens increased their target price on Repligen from $180.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, August 3rd. Deutsche Bank Aktiengesellschaft lowered their target price on Repligen from $180.00 to $165.00 in a research note on Wednesday, May 3rd. Finally, Craig Hallum decreased their price target on shares of Repligen from $207.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Comerica Bank bought a new position in Repligen during the 2nd quarter worth $1,207,000. Teachers Retirement System of The State of Kentucky increased its position in Repligen by 10.3% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 9,121 shares of the biotechnology company’s stock worth $1,291,000 after buying an additional 848 shares during the period. Nuveen Asset Management LLC increased its position in Repligen by 4.8% during the 2nd quarter. Nuveen Asset Management LLC now owns 214,135 shares of the biotechnology company’s stock worth $30,292,000 after buying an additional 9,825 shares during the period. Neo Ivy Capital Management bought a new position in Repligen during the 2nd quarter worth $296,000. Finally, IMA Wealth Inc. increased its position in shares of Repligen by 2.5% in the second quarter. IMA Wealth Inc. now owns 9,301 shares of the biotechnology company’s stock worth $1,316,000 after purchasing an additional 227 shares during the period. Institutional investors own 97.64% of the company’s stock.
Repligen Price Performance
Shares of RGEN stock opened at $172.56 on Thursday. The stock has a market cap of $9.62 billion, a PE ratio of 71.31, a price-to-earnings-growth ratio of 3.78 and a beta of 1.01. The stock has a 50-day moving average of $160.14 and a 200-day moving average of $165.03. Repligen has a one year low of $134.64 and a one year high of $235.06.
Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.04. Repligen had a return on equity of 7.83% and a net margin of 18.92%. The company had revenue of $159.20 million during the quarter, compared to analysts’ expectations of $165.93 million. During the same period in the prior year, the business posted $0.91 EPS. Repligen’s revenue was down 23.3% on a year-over-year basis. As a group, research analysts anticipate that Repligen will post 1.83 earnings per share for the current year.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Five stocks we like better than Repligen
- The “How” and “Why” of Investing in 5G Stocks
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- Dividend Capture Strategy: What You Need to Know
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- Roth IRA Calculator: Calculate Your Potential Returns
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.